Back to search results

ChromoSeq® for Acute Lymphoblastic Leukemia (ALL) Patients

This study is looking at a test called ChromoSeq® to see how well it works for children and young adults (under 30 years old) with acute lymphoblastic leukemia (ALL). Researchers want to see if this test can help classify ALL right when it's first diagnosed or when it comes back. You would provide a bone marrow and/or blood sample for the ChromoSeq® test. The main goal is to measure how successful the ChromoSeq® test is, which means how often it provides results within about 15 days. This study is currently unclear about its recruitment status.

Study design
This is an observational study collecting samples from 60 participants to evaluate a new test.
What's involved
You would provide a bone marrow and/or peripheral blood sample at the time of initial workup.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for clinical outcomes for up to 65 months after the initial sample collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07313592

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

Suspended
Not specifiedUp to 30Observational
Washington University School of Medicine
~60 participants
Updated 2026-09-14 on ClinicalTrials.gov
What's tested:ChromoSeq® assay testing

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of success of ChromoSeq®
Measured over Time of specimen collection to completion of results (total estimated time is 15 days)

Conditions

Acute Lymphoblastic Leukemia

Explore related trials

Acute Lymphoblastic Leukemia

NCT07313592

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Washington University School of Medicine/St. Louis Children's Hospital

    St Louis, Missourino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Margaret Ferris, MD, PhD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Rate of success of ChromoSeq®Time of specimen collection to completion of results (total estimated time is 15 days)

    ChromoSeq® will be successful if the results on the first attempt in a real-time, clinical setting identifies recurrent structural variants and copy number alterations of conventional cytogenetics and karyotype. The success rate and the 95% confidence interval will be calculated.